Eton Pharmaceuticals Inc
NASDAQ:ETON
Intrinsic Value
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. [ Read More ]
The intrinsic value of one ETON stock under the Base Case scenario is 5.36 USD. Compared to the current market price of 3.06 USD, Eton Pharmaceuticals Inc is Undervalued by 43%.
Valuation Backtest
Eton Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling ETON stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Eton Pharmaceuticals Inc
Current Assets | 26.8m |
Cash & Short-Term Investments | 21.4m |
Receivables | 3.4m |
Other Current Assets | 2m |
Non-Current Assets | 4.9m |
PP&E | 150k |
Intangibles | 4.7m |
Other Non-Current Assets | 12k |
Current Liabilities | 16.2m |
Accounts Payable | 1.8m |
Accrued Liabilities | 9m |
Other Current Liabilities | 5.4m |
Non-Current Liabilities | 22k |
Other Non-Current Liabilities | 22k |
Earnings Waterfall
Eton Pharmaceuticals Inc
Revenue
|
31.6m
USD
|
Cost of Revenue
|
-10.6m
USD
|
Gross Profit
|
21.1m
USD
|
Operating Expenses
|
-22.3m
USD
|
Operating Income
|
-1.2m
USD
|
Other Expenses
|
256k
USD
|
Net Income
|
-936k
USD
|
Free Cash Flow Analysis
Eton Pharmaceuticals Inc
What is Free Cash Flow?
ETON Profitability Score
Profitability Due Diligence
Eton Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Eton Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
ETON Solvency Score
Solvency Due Diligence
Eton Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Eton Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ETON Price Targets Summary
Eton Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ETON is 10.2 USD with a low forecast of 10.1 USD and a high forecast of 10.5 USD.
Ownership
ETON Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ETON Price
Eton Pharmaceuticals Inc
Average Annual Return | -18.36% |
Standard Deviation of Annual Returns | 25.68% |
Max Drawdown | -80% |
Market Capitalization | 78.6m USD |
Shares Outstanding | 25 690 000 |
Percentage of Shares Shorted | 0.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
Contact
IPO
Employees
Officers
The intrinsic value of one ETON stock under the Base Case scenario is 5.36 USD.
Compared to the current market price of 3.06 USD, Eton Pharmaceuticals Inc is Undervalued by 43%.